KANSAS CITY, Mo., and ALBUQUERQUE, N.M. - March 10, 2008 - Cerner Corporation (NASDAQ: CERN), the University of New Mexico Health Sciences Center (UNM HSC) College of Pharmacy, the UNM School of Engineering and STC.UNM (STC), the University’s technology-transfer corporation, announced today the signing of a Sponsored Research Agreement to evaluate UNM HSC’s dry-powder inhaler (DPI) drug-delivery technology for use in both pulmonary and systemic conditions, like asthma and chronic obstructive lung disease. Upon completion of the research studies, the agreement provides Cerner an option for exclusive licensing of UNM HSC’s technology for clinical and commercial use worldwide.
Cerner’s depth of research experience and proven ability to connect retrospective information with real-time point of care makes a difference for people living with chronic disease every day. This Sponsored Research Agreement is a clear opportunity for Cerner and UNM HSC to make a difference for people who could benefit from this new type of inhaler technology.
"Based upon its impressive capabilities for dispersal of particles with only small inspiratory effort, we believe UNM HSC’s DPI technology can become an important addition to the therapeutic armamentarium, especially for indications that affect children and the elderly," said Douglas McNair, M.D., Ph.D., Cerner Senior Vice President for Clinical Research. "We believe UNM HSC’s technology can contribute significantly in addressing higher morbidity populations and indications than presently available inhaler devices. Our enthusiasm for this opportunity is based in part on our data mining of de-identified and confidentiality-protected clinical data which revealed relatively large gaps in existing systemic therapeutics and incomplete coverage by pulmonary delivery modalities that exist today."
"We are extremely pleased to be working with Cerner to advance the state-of-the-art in drug-delivery by the pulmonary route," said Hugh Smyth, Ph.D., UNM HSC Assistant Professor, Division of Pharmaceutical Sciences at the College of Pharmacy. "Bench-testing and initial human studies of our aeroelastic dispersion technology have shown promise, and suggest that it is capable of producing consistent deposition in the deep lung. The comparatively low pressure gradient required should enable this device to address various important unmet needs, not just in ambulatory patients with chronic conditions but in certain in-patient acute-care indications as well."
Elizabeth Kuuttila, STC.UNM President and CEO, said, "Cerner’s readiness to partner with the University validates both the enablement of our DPI drug-delivery technology platform and their leadership as an informatics-based life sciences development company."
Cerner currently is one of the only health information technology company working to develop both drug and healthcare device solutions. Financial terms of the agreement were not disclosed.